Prescription Drugs Companies Typically Charge More In The United States Than In Canada
Download Prescription Drugs Companies Typically Charge More In The United States Than In Canada full books in PDF, epub, and Kindle. Read online free Prescription Drugs Companies Typically Charge More In The United States Than In Canada ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 235 |
Release | : 2018-03-01 |
Genre | : Medical |
ISBN | : 0309468086 |
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author | : DIANE Publishing Company |
Publisher | : DIANE Publishing |
Total Pages | : 186 |
Release | : 2004 |
Genre | : |
ISBN | : 9780788115899 |
Examines the extent to which drug manufacturers charge more for the same products in the U.S. than abroad. Also, studied manufacturers' "factory prices" and identified the causes of any documented price differentials. Compares factory prices for the top 200 frequently dispensed prescription drugs sold in both the U.S. and the U.K. 7 charts and tables.
Author | : United States. General Accounting Office |
Publisher | : |
Total Pages | : 58 |
Release | : 1994 |
Genre | : Drugs |
ISBN | : |
Author | : Elizabeth R. Nesbitt |
Publisher | : DIANE Publishing |
Total Pages | : 246 |
Release | : 2000 |
Genre | : Drugs |
ISBN | : 145782342X |
Author | : United States. Congress. House. Committee on Ways and Means. Subcommittee on Health |
Publisher | : |
Total Pages | : 428 |
Release | : 1993 |
Genre | : Digital images |
ISBN | : |
Author | : Sarah F. Jaggar |
Publisher | : |
Total Pages | : 12 |
Release | : 1994 |
Genre | : Drugs |
ISBN | : |
Author | : Jonathan Ratner |
Publisher | : DIANE Publishing |
Total Pages | : 108 |
Release | : 1994-09 |
Genre | : Medical |
ISBN | : 9780788111723 |
Author | : United States. General Accounting Office |
Publisher | : |
Total Pages | : 84 |
Release | : 1992 |
Genre | : Medicare |
ISBN | : |
Author | : United States. Congress. Senate. Committee on Governmental Affairs |
Publisher | : |
Total Pages | : 258 |
Release | : 1995 |
Genre | : Business & Economics |
ISBN | : |
Author | : Marcia Angell |
Publisher | : Random House Trade Paperbacks |
Total Pages | : 354 |
Release | : 2005-08-09 |
Genre | : Business & Economics |
ISBN | : 0375760946 |
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.